Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia

Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center. Patients received ofatumumab (300 mg then 1000 mg weekly for 12 weeks) and methylpre...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, J E, Choi, M Y, Carvajal, T, Almahasnah, E, Chang, J, James, D F, Kipps, T J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571984/
https://www.ncbi.nlm.nih.gov/pubmed/25397619
http://dx.doi.org/10.1038/bcj.2014.76

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571984/
https://www.ncbi.nlm.nih.gov/pubmed/25397619
http://dx.doi.org/10.1038/bcj.2014.76

Ejemplares similares